

To: Business Editor
[For immediate release]



Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司

Lee's Pharm Becomes a Constituent Stock of MSCI China Index under MSCI Global Small Cap Indexes

* * * * *

Enhances the Reputation and Position in the International Capital Market

[10 November 2014 - Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, is pleased to announce that the Company will be added as a constituent stock of Morgan Stanley Capital International ("MSCI") China Index under MSCI Global Small Cap Indexes, effective as of the Hong Kong stock market close on 25 November 2014.

Commenting on the inclusion to the MSCI China Index under Global Small Cap Indexes, **Dr. Benjamin Li, Executive Director and Chief Executive Officer of the Group**, said, "The inclusion will further enhance our reputation and position in the international capital market and demonstrate the global recognition of Lee's Pharm amongst investors. Looking ahead, as a leading integrated research-driven and market-oriented pharmaceutical group in China, the Group will continue to enhance the existing competitiveness and bring satisfactory returns to the shareholders."

MSCI indexes have become one of the most widely used international equity benchmarks by institutional investors. It covers companies with good operational results and potential. Changes to the MSCI indexes may lead to the adjustment or rebalance of portfolios of a large number of institutional investors.

- End -

About Lee's Pharmaceutical Holdings Limited

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspires to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's Pharm is available at www.leespharm.com.

Issued by Porda Havas International Finance Communications Group for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Keely Chan	+852 3150 6760	keely.chan@pordahavas.com
Cherry Cheung	+852 3150 6773	cherry.cheung@pordahavas.com
Sophie Zhang	+852 3150 6742	sophie.zhang@pordahavas.com
Mandy Zhang	+852 3150 6765	mandy.zhang@pordahavas.com
Claire Li	+852 3150 6711	claire.li@pordahavas.com

Fax: +852 3150 6728